

Anti-hCD20-hIgG2

Monoclonal human IgG2 antibody against human CD20

Catalog code: hcd20-mab2, hcd20-mab2-03

<https://www.invivogen.com/anti-human-cd20-igg2-rituximab>

For research use only, not for diagnostic or therapeutic use

Version 23L21-MM

PRODUCT INFORMATION

Contents: Anti-hCD20-hIgG2 purified monoclonal antibody (mAb) is provided azide-free and lyophilized. It is available in two quantities:

hcd20-mab2: 100 µg Anti-hCD20-hIgG2

hcd20-mab2-03: 3 x 100 µg Anti-hCD20-hIgG2

Target: Human CD20

Clonality: Monoclonal antibody

Isotype: Human IgG2, kappa

Source: CHO cells

Formulation: 0.2 µm filtered solution in sodium phosphate buffer with glycine, saccharose, and stabilizing agents

Purity: Purified by affinity chromatography with protein G

Storage and stability

- Product is shipped at room temperature. Upon receipt, store at -20°C.

- Reconstituted antibody is stable for 1 month when stored at 4°C and for 1 year when aliquoted and stored at -20°C. Avoid repeated freeze-thaw cycles.

Quality control

- Binding to human CD20 has been tested using flow cytometry.

- The complete sequence of this antibody has been verified.

- The absence of bacterial contamination (e.g. lipoproteins and endotoxins) has been confirmed using HEK-Blue™ TLR2 and HEK-Blue™ TLR4 cells.

DESCRIPTION

Anti-hCD20-hIgG2 features the constant region of the human IgG2 isotype and the variable region of rituximab. Rituximab is a mouse/human chimeric monoclonal antibody that targets the CD20 antigen found on the surface of malignant and normal B lymphocytes. Binding of rituximab to CD20 results in cell destruction through different mechanisms including direct signaling of apoptosis, complement activation and cell-mediated cytotoxicity. Rituximab has been approved by the FDA for the treatment of various lymphoid malignancies, including B-cell non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia.

Human IgG2 is the second most common antibody present in serum. Human IgG2 is resistant to cleavage by proteolytic enzymes, due to a short hinge region. Human IgG2 displays low complement-dependent cytotoxicity (CDC) and very low antibody-dependent cell-mediated cytotoxicity (ADCC).

Anti-hCD20-hIgG2 was generated by recombinant DNA technology. It has been produced in CHO cells and purified by affinity chromatography with protein G.

APPLICATIONS

Anti-hCD20-hIgG2 targets the human CD20 antigen found on the surface of malignant and normal B lymphocytes.

ANTIBODY ISOTYPE COLLECTION

For your research, InvivoGen provides an anti-hCD20 isotype collection. This collection consists of monoclonal antibodies comprising the variable region of rituximab, and the constant region of human (h) and mouse (m) isotypes; hlgG1, hlgG1fut, hlgG1NQ, hlgG2, hlgG3, hlgG4, hlgG4(S228P), hlgA2, mlgG1, and mlgG2a. The isotypes differ in their functional locations and effector functions, such as complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC), as presented in the table below.

Effector functions	Human isotypes							Mouse isotypes	
	IgG1	IgG1 fut	IgG1 NQ	IgG2	IgG3	IgG4 and IgG4 (S228P)	IgA2	IgG1	IgG2a
ADCC	++	++++	-	+/-	++	+/-	+	+/-	++
ADCP	+++	+++	-	+/-	++	+	+	+	+++
CDC	++	++	+/-	+	+++	-	-	-	++

METHODS

Antibody resuspension (100 µg/ml)

Note: Ensure you see the lyophilized pellet before resuspension.

- Add 1 ml of sterile water to 100 µg and gently pipette until completely resuspended.

RELATED PRODUCTS

Product	Catalog Code
Anti-β-Gal-hIgG2 (isotype control)	bgal-mab2
Anti-hCD20-hIgA2	hcd20-mab7
Anti-hCD20-hIgG1	hcd20-mab1
Anti-hCD20-hIgG1fut	hcd20-mab13
Anti-hCD20-hIgG1NQ	hcd20-mab12
Anti-hCD20-hIgG3	hcd20-mab3
Anti-hCD20-hIgG4	hcd20-mab4
Anti-hCD20-hIgG4 (S228P)	hcd20-mab14
Anti-hCD20-mlgG1	hcd20-mab9
Anti-hCD20-mlgG2a	hcd20-mab10

Other antibody isotype families are available, such as Anti-hTNF-α, Anti-hPD1 and Anti-βGal (control). For more information, please visit www.invivogen.com/biosimilar-antibody-isotypes.

TECHNICAL SUPPORT

InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Asia: +852 3622-3480

E-mail: info@invivogen.com